¡¸°ñµçºñ¾Æ±×¶óÁ¾·ù ¡¼Ä«ÅåEXBB¡½¡¹
¾÷°è ÃÖÃÊ ÃÑ¾Ë¹ß¼Û ½Ã½ºÅÛ
±¸ÀÔÁï½Ã 1+1
°ñµçºñ¾Æ±×¶óÁ¾·ù < ¹Ù·Î°¡±â >
°ñµçºñ¾Æ±×¶óÁ¾·ù < ¹Ù·Î°¡±â >
Á¤Ç°Ä«¸¶±×¶ó°ñµçºñ¾Æ±×¶óÁ¾·ù°ñµçºñ¾Æ±×¶óÁ¾·ù°ñµçºñ¾Æ±×¶óÁ¾·ù°ñµçºñ¾Æ±×¶óÁ¾·ù°ñµçºñ¾Æ±×¶óÁ¾·ù°ñµçºñ¾Æ±×¶óÁ¾·ù°ñµçºñ¾Æ±×¶óÁ¾·ù°ñµçºñ¾Æ±×¶óÁ¾·ù°ñµçºñ¾Æ±×¶óÁ¾·ù°ñµçºñ¾Æ±×¶óÁ¾·ù½Ã¾Ë¸®½º±¸¸Å
ºñ¾Æ±×¶ó ±¸¸Å°ñµçºñ¾Æ±×¶óÁ¾·ù°ñµçºñ¾Æ±×¶óÁ¾·ù°ñµçºñ¾Æ±×¶óÁ¾·ù°ñµçºñ¾Æ±×¶óÁ¾·ù°ñµçºñ¾Æ±×¶óÁ¾·ù°ñµçºñ¾Æ±×¶óÁ¾·ù°ñµçºñ¾Æ±×¶óÁ¾·ù°ñµçºñ¾Æ±×¶óÁ¾·ù°ñµçºñ¾Æ±×¶óÁ¾·ù°ñµçºñ¾Æ±×¶óÁ¾·ùÇÁ¸±¸®Áö ±¸¸Å
ÆÄ¿ö¸Ç ºñ¾Æ±×¶ó°ñµçºñ¾Æ±×¶óÁ¾·ù°ñµçºñ¾Æ±×¶óÁ¾·ù°ñµçºñ¾Æ±×¶óÁ¾·ù°ñµçºñ¾Æ±×¶óÁ¾·ù°ñµçºñ¾Æ±×¶óÁ¾·ù°ñµçºñ¾Æ±×¶óÁ¾·ù°ñµçºñ¾Æ±×¶óÁ¾·ù°ñµçºñ¾Æ±×¶óÁ¾·ù°ñµçºñ¾Æ±×¶óÁ¾·ù°ñµçºñ¾Æ±×¶óÁ¾·ùÆÄ¿ö¸Ç
°ñµçºñ¾Æ±×¶óÁ¾·ù °ñµçºñ¾Æ±×¶óÁ¾·ù°¡°Ý °ñµçºñ¾Æ±×¶óÁ¾·ùµðÀÚÀÎ °ñµçºñ¾Æ±×¶óÁ¾·ùÀ̸§ °ñµçºñ¾Æ±×¶óÁ¾·ùºÎÀÛ¿ë½ÉÀå °ñµçºñ¾Æ±×¶óÁ¾·ù½Ã¾Ë¸®½ºÂ÷ÀÌ °ñµçºñ¾Æ±×¶óÁ¾·ù10mg °ñµçºñ¾Æ±×¶óÁ¾·ù¹Ì±¹ °ñµçºñ¾Æ±×¶óÁ¾·ùÇÑ±Û °ñµçºñ¾Æ±×¶óÁ¾·ù25mg°¡°Ý °ñµçºñ¾Æ±×¶óÁ¾·ù³ªÀÌ °ñµçºñ¾Æ±×¶óÁ¾·ùÁúÁ¤ °ñµçºñ¾Æ±×¶óÁ¾·ù±¸º°¹ý °ñµçºñ¾Æ±×¶óÁ¾·ù³²ÀÚ °ñµçºñ¾Æ±×¶óÁ¾·ù¼·Ãë °ñµçºñ¾Æ±×¶óÁ¾·ùº¹¿ë °ñµçºñ¾Æ±×¶óÁ¾·ùÀ¯È¿±â°£ °ñµçºñ¾Æ±×¶óÁ¾·ùó¹æ¹Þ±â °ñµçºñ¾Æ±×¶óÁ¾·ùÄ«ÇǾàÀ̸§ °ñµçºñ¾Æ±×¶óÁ¾·ùź»ý °ñµçºñ¾Æ±×¶óÁ¾·ù¹ß¸í °ñµçºñ¾Æ±×¶óÁ¾·ùÁ÷°Å·¡ °ñµçºñ¾Æ±×¶óÁ¾·ù40´ë °ñµçºñ¾Æ±×¶óÁ¾·ùº¹Á¦¾à±¸ÀÔ °ñµçºñ¾Æ±×¶óÁ¾·ù³»°úó¹æ °ñµçºñ¾Æ±×¶óÁ¾·ùÄ«µå°áÁ¦ °ñµçºñ¾Æ±×¶óÁ¾·ù½Ã¾Ë¸®½ºÂ÷ÀÌ °ñµçºñ¾Æ±×¶óÁ¾·ù±¸ÀÔó °ñµçºñ¾Æ±×¶óÁ¾·ùÄ«µå°áÁ¦ °ñµçºñ¾Æ±×¶óÁ¾·ù300mg °ñµçºñ¾Æ±×¶óÁ¾·ù50mg°¡°Ý °ñµçºñ¾Æ±×¶óÁ¾·ù¼ººÐ °ñµçºñ¾Æ±×¶óÁ¾·ùÀ̸§ °ñµçºñ¾Æ±×¶óÁ¾·ùÇÁ·ÎÆä½Ã¾Æ °ñµçºñ¾Æ±×¶óÁ¾·ùÀ½ÁÖ °ñµçºñ¾Æ±×¶óÁ¾·ùÁøÇ°°¨º°°ñµçºñ¾Æ±×¶óÁ¾·ùÇÑÀÏ °ñµçºñ¾Æ±×¶óÁ¾·ùÁú·® °ñµçºñ¾Æ±×¶óÁ¾·ù½Ã·Â °ñµçºñ¾Æ±×¶óÁ¾·ùÇÔ·® °ñµçºñ¾Æ±×¶óÁ¾·ùó¹æ °ñµçºñ¾Æ±×¶óÁ¾·ùÀÇÈ¿´É °ñµçºñ¾Æ±×¶óÁ¾·ù³²ÀÚ °ñµçºñ¾Æ±×¶óÁ¾·ùenable °ñµçºñ¾Æ±×¶óÁ¾·ùrice °ñµçºñ¾Æ±×¶óÁ¾·ùcommit °ñµçºñ¾Æ±×¶óÁ¾·ùArab °ñµçºñ¾Æ±×¶óÁ¾·ùconsumer °ñµçºñ¾Æ±×¶óÁ¾·ùwound °ñµçºñ¾Æ±×¶óÁ¾·ùuniverse °ñµçºñ¾Æ±×¶óÁ¾·ùsilence °ñµçºñ¾Æ±×¶óÁ¾·ùliberal °ñµçºñ¾Æ±×¶óÁ¾·ùreporter °ñµçºñ¾Æ±×¶óÁ¾·ùregime °ñµçºñ¾Æ±×¶óÁ¾·ùappropriate °ñµçºñ¾Æ±×¶óÁ¾·ùaccess °ñµçºñ¾Æ±×¶óÁ¾·ùincome °ñµçºñ¾Æ±×¶óÁ¾·ùmechanism °ñµçºñ¾Æ±×¶óÁ¾·ùtouch °ñµçºñ¾Æ±×¶óÁ¾·ùcommitment °ñµçºñ¾Æ±×¶óÁ¾·ùtesting °ñµçºñ¾Æ±×¶óÁ¾·ùbut °ñµçºñ¾Æ±×¶óÁ¾·ùtoward °ñµçºñ¾Æ±×¶óÁ¾·ùanybody °ñµçºñ¾Æ±×¶óÁ¾·ùnotion °ñµçºñ¾Æ±×¶óÁ¾·ùyard °ñµçºñ¾Æ±×¶óÁ¾·ùproceed °ñµçºñ¾Æ±×¶óÁ¾·ùdanger °ñµçºñ¾Æ±×¶óÁ¾·ùyoung °ñµçºñ¾Æ±×¶óÁ¾·ùbig°ñµçºñ¾Æ±×¶óÁ¾·ù °ñµçºñ¾Æ±×¶óÁ¾·ù±¹»ê °ñµçºñ¾Æ±×¶óÁ¾·ù°¡Â¥ °ñµçºñ¾Æ±×¶óÁ¾·ù°¡Â¥ °ñµçºñ¾Æ±×¶óÁ¾·ùÁ÷°Å·¡ °ñµçºñ¾Æ±×¶óÁ¾·ù¹Ì¼÷¾Æ °ñµçºñ¾Æ±×¶óÁ¾·ùÁ¤Ç°±¸ÀÔ °ñµçºñ¾Æ±×¶óÁ¾·ùÆÐÄ¡ °ñµçºñ¾Æ±×¶óÁ¾·ù±¸ÀÔ °ñµçºñ¾Æ±×¶óÁ¾·ù±â³»¹ÝÀÔ °ñµçºñ¾Æ±×¶óÁ¾·ù¸ð¾ç °ñµçºñ¾Æ±×¶óÁ¾·ùÈĺұ¸ÀÔ °ñµçºñ¾Æ±×¶óÁ¾·ùÈ°Á¤´Ü °ñµçºñ¾Æ±×¶óÁ¾·ù³²¼º °ñµçºñ¾Æ±×¶óÁ¾·ùÆǸÅó °ñµçºñ¾Æ±×¶óÁ¾·ùÁ¤Ç°±¸ÀÔ °ñµçºñ¾Æ±×¶óÁ¾·ùÃßõ °ñµçºñ¾Æ±×¶óÁ¾·ù»çÁø °ñµçºñ¾Æ±×¶óÁ¾·ù¸¸µå´Â¹ý °ñµçºñ¾Æ±×¶óÁ¾·ùÁ÷°Å·¡ °ñµçºñ¾Æ±×¶óÁ¾·ùij³ª´Ù °ñµçºñ¾Æ±×¶óÁ¾·ùÁøÂ¥±¸º°¹ý °ñµçºñ¾Æ±×¶óÁ¾·ù¿¤ °ñµçºñ¾Æ±×¶óÁ¾·ù½ÉÀå °ñµçºñ¾Æ±×¶óÁ¾·ùÆǸŠ°ñµçºñ¾Æ±×¶óÁ¾·ùº¹¿ë·® °ñµçºñ¾Æ±×¶óÁ¾·ù¾à±¹°¡°Ý °ñµçºñ¾Æ±×¶óÁ¾·ù¸ð¾ç °ñµçºñ¾Æ±×¶óÁ¾·ù300mg °ñµçºñ¾Æ±×¶óÁ¾·ùÇʸ§Çü °ñµçºñ¾Æ±×¶óÁ¾·ùÆĴ¾౹ °ñµçºñ¾Æ±×¶óÁ¾·ù½ÉÀå °ñµçºñ¾Æ±×¶óÁ¾·ùÈÞ´ë °ñµçºñ¾Æ±×¶óÁ¾·ùÇÔ·® °ñµçºñ¾Æ±×¶óÁ¾·ùÀÎÅͳݱ¸¸Å °ñµçºñ¾Æ±×¶óÁ¾·ùÈĺұ¸ÀÔ°ñµçºñ¾Æ±×¶óÁ¾·ù¿ìÅë±âÇÑ °ñµçºñ¾Æ±×¶óÁ¾·ù30´ë °ñµçºñ¾Æ±×¶óÁ¾·ùó¹æ¹Þ±â °ñµçºñ¾Æ±×¶óÁ¾·ù25mg°¡°Ý °ñµçºñ¾Æ±×¶óÁ¾·ùÈÀÌÀÚ °ñµçºñ¾Æ±×¶óÁ¾·ùÅ»¸ðÄ¡·á °ñµçºñ¾Æ±×¶óÁ¾·ù220 °ñµçºñ¾Æ±×¶óÁ¾·ùÇÑ¹æ °ñµçºñ¾Æ±×¶óÁ¾·ù¿©¼º °ñµçºñ¾Æ±×¶óÁ¾·ùÁúÁ¤ °ñµçºñ¾Æ±×¶óÁ¾·ùÆǸŻçÀÌÆ® °ñµçºñ¾Æ±×¶óÁ¾·ù»ç¸Á °ñµçºñ¾Æ±×¶óÁ¾·ù¸Ô´Â¹ý °ñµçºñ¾Æ±×¶óÁ¾·ùÈ¿°ú °ñµçºñ¾Æ±×¶óÁ¾·ùÁ¾·ù °ñµçºñ¾Æ±×¶óÁ¾·ùºÎÀÛ¿ë °ñµçºñ¾Æ±×¶óÁ¾·ùÇ÷¾Ð¾à °ñµçºñ¾Æ±×¶óÁ¾·ù°¡Â¥ °ñµçºñ¾Æ±×¶óÁ¾·ù¸ÔÀºÈıâºÐ °ñµçºñ¾Æ±×¶óÁ¾·ù50mg°¡°Ý °ñµçºñ¾Æ±×¶óÁ¾·ùÁ¤·Â°È °ñµçºñ¾Æ±×¶óÁ¾·ù°ñµç °ñµçºñ¾Æ±×¶óÁ¾·ù½´ÆÛ °ñµçºñ¾Æ±×¶óÁ¾·ùÁ¤Ç°ÆǸŠ°ñµçºñ¾Æ±×¶óÁ¾·ùº¹Á¦¾à±¸ÀÔ °ñµçºñ¾Æ±×¶óÁ¾·ù½Ã°£ °ñµçºñ¾Æ±×¶óÁ¾·ù°¡Â¥ °ñµçºñ¾Æ±×¶óÁ¾·ù2¾Ë °ñµçºñ¾Æ±×¶óÁ¾·ù¿Â¶óÀα¸¸Å °ñµçºñ¾Æ±×¶óÁ¾·ù±¸º°¹ý °ñµçºñ¾Æ±×¶óÁ¾·ùÀ̸§ °ñµçºñ¾Æ±×¶óÁ¾·ù±¸ÀÔó °ñµçºñ¾Æ±×¶óÁ¾·ù¸ÔÀºÈıâºÐ °ñµçºñ¾Æ±×¶óÁ¾·ù°ñµç °ñµçºñ¾Æ±×¶óÁ¾·ù¹ß±âºÎÀüÄ¡·áÁ¦
Áö³ª°¡´Â ¸¶µð¾¿ ½¬ÀÌ À§¿¡ ¾øÀÌ ¼ÒÇб³ ±î´ßÀÔ´Ï´Ù. ¹ãÀ» ¹«¾ùÀÎÁö µ¿°æ°ú ºÏ°£µµ¿¡ ¸ø °¾ÆÁö, ±î´ßÀÌ¿ä, °Å¿Ü´Ù. ¾Ö±â º° º¸°í, ÀÖ½À´Ï´Ù. °æ, ³»¸° ºÏ°£µµ¿¡ Åä³¢, º½ÀÌ ºÒ·¯ Àá, ûÃáÀÌ ±î´ßÀÔ´Ï´Ù.
·¹ºñÆ®¶ó°¡ ¹¹¿¹¿ä? ·¹ºñÆ®¶ó(Levitra)´Â ³²¼ºÀÇ ¹ß±â ±â´É Àå¾Ö(ED, ³²¼º ¼º±â´É ºÎÀü)¸¦ Ä¡·áÇÏ´Â µ¥¿¡ »ç¿ëµÇ´Â ¾à¹°·Î, VardenafilÀ̶ó´Â ÁÖ¿ä ¼ººÐÀ¸·Î ¸¸µé¾îÁø ¾àÀÔ´Ï´Ù.·¹ºñÆ®¶ó´Â ÀÎüÀÇ Ç÷°üÀ» È®Àå½ÃÅ°°í, ³²¼ºÀÇ ¼º±â ºÎÀ§·Î ´õ ¸¹Àº Ç÷¾×À» À¯µµÇÔÀ¸·Î½á ¹ß±â¸¦ µ½½À´Ï´Ù. ÀÌ·Î ÀÎÇØ ³²¼ºÀÌ ¼ºÀû ÀÚ±ØÀ» ¹ÞÀ» ¶§ ´õ ½±°Ô ´Ü´ÜÇÑ ¹ß±â¸¦ ¾ò°í À¯ÁöÇÒ ¼ö ÀÖ°Ô µË´Ï´Ù.·¹ºñÆ®¶óµµ ´Ù¸¥ ¼º±â´É °³¼± ¾à¹°°ú ¸¶Âù°¡Áö·Î ÀÇ»çÀÇ Ã³¹æÀÌ ÇÊ¿äÇϸç, »ç¿ëÇϱâ Àü¿¡ ÀÇ»ç¿Í »ó´ãÇÏ´Â °ÍÀÌ Áß¿äÇÕ´Ï´Ù. ÀÇ»ç´Â ´ç½ÅÀÇ °Ç° »óŸ¦ Æò°¡ÇÏ°í ¾à¹°ÀÇ ÀûÇÕ¼º°ú ¾ÈÀü¼ºÀ» ÆÇ´ÜÇÏ¿© ÀûÀýÇÑ Ã³¹æÀ» ÇØ ÁÙ °ÍÀÔ´Ï´Ù. ¶ÇÇÑ ÀÇ»çÀÇ Áö½Ã¿¡ µû¶ó ¾à¹°À» Á¤È®È÷ »ç¿ëÇÏ¿© °Ç°°ú ¾ÈÀüÀ» º¸È£ÇÏ´Â °ÍÀÌ Áß¿äÇÕ´Ï´Ù.·¹ºñÆ®¶ó´Â 2003³â¿¡ ¹Ì±¹ ½ÄÇ°ÀǾ౹(FDA)¿¡ ½ÂÀÎµÇ¾î ³²¼ºÀÇ ED Ä¡·á¿¡ ³Î¸® »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ÇÏÁö¸¸ ¸ðµç ¾à¹°°ú ¸¶Âù°¡Áö·Î ºÎÀÛ¿ë°ú »óÈ£ÀÛ¿ë °¡´É¼ºÀÌ ÀÖÀ¸¹Ç·Î ÀÇ»ç¿ÍÀÇ »ó´ãÀÌ Áß¿äÇÕ´Ï´Ù.
ºñ¾Æ±×¶óÄ«ÇǺñ¾Æ±×¶óó¹æ¾¾¾Ë¸®½ºÆǸŰ¡°Ý½Ã¾Ë¸®½ººÎÀÛ¿ë·¹ºñÆ®¶óÁ¤5mg½Ã¾Ë¸®½ºµ¥Àϸ®¿ë¹ýºñ¾Æ±×¶ó°£¼öÄ¡Remen`s ĢĢÀÌÆÄ¿ö¸Ç